⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Neoadjuvant Therapy in Advanced Ovarian Cancer With Avastin

Official Title: A Randomized Phase II Multi-centric Open Label Clinical Trial to Determine the Efficacy and Toxicity of Preoperative Chemotherapy With or Without Bevacizumab in Patients With Advanced Ovarian Cancer

Study ID: NCT01847677

Conditions

Cancer, Ovarian

Study Description

Brief Summary: Recently results have shown that Bevacizumab is active both in monotherapy and in combination therapy in patients with ovarian cancer. One of our objectives is to evaluate whether the addition of neoadjuvant bevacizumab improves the response and whether this affects the evolution of patients.

Detailed Description: Epithelial ovarian cancer (OC) is the fourth leading cause of cancer death in women, after lung, breast and colon cancer, and it represents the most common cause of death from gynaecological malignancies. The high mortality associated with OC is due to the lack of screening tests that enable an early diagnosis, thus the majority of patients are diagnosed at advanced stages of the disease when the chances of a cure are very limited. In fact, the 5-year overall survival (OS) rate for stage III-IV OC does not exceed 20-30% in many series. The standard treatment for advanced OC is maximal cytoreductive surgery (or debulking) followed by the administration of 6 cycles of adjuvant chemotherapy with carboplatin and paclitaxel. In recent years, a number of studies have been carried out with antiangiogenic drugs. Specifically, bevacizumab, an anti-VEGF monoclonal antibody, has been shown to be active both in monotherapy and combination therapy in patients with OC that have received multiple previous lines of chemotherapy. One of the objectives is to evaluate whether the addition of neoadjuvant bevacizumab improves the response and whether this affects the evolution of patients.

Eligibility

Minimum Age: 18 Years

Eligible Ages: ADULT, OLDER_ADULT

Sex: FEMALE

Healthy Volunteers: No

Locations

Hospital La Fe, Valencia, Comunidad Valenciana, Spain

Hospital Germans Trias i Pujol, Badalona, , Spain

Hospital Clínic, Barcelona, , Spain

Hospital Sant Pau, Barcelona, , Spain

H. Reina Sofia, Cordoba, , Spain

ICO Girona, Girona, , Spain

ICO Hospitalet, Hospitalet del Llobregat, , Spain

Hospital 12 de Octubre, Madrid, , Spain

Hospital Clínico San Carlos, Madrid, , Spain

Hospital Universitario Morales Meseguer, Murcia, , Spain

Hospital Son Llatzer, Palma Mallorca, , Spain

Parc Taulí, Sabadell, , Spain

Hospital Marqués de Valdecilla, Santander, , Spain

Contact Details

Name: Yolanda García, MD

Affiliation: C.S Parc Taulí

Role: STUDY_CHAIR

Useful links and downloads for this trial

Clinicaltrials.gov

Google Search Results

Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: